Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan

Detalles Bibliográficos
Autores principales: Huang, Yen-Hsiang, Hsu, Kuo-Hsuan, Tseng, Jeng-Sen, Yang, Tsung-Ying, Chen, Kun-Chieh, Su, Kang-Yi, Yu, Sung-Liang, Chen, Jeremy J. W., Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928810/
https://www.ncbi.nlm.nih.gov/pubmed/36334173
http://dx.doi.org/10.1007/s11523-022-00928-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928810/
https://www.ncbi.nlm.nih.gov/pubmed/36334173
http://dx.doi.org/10.1007/s11523-022-00928-4

Ejemplares similares